Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Biopharmaceutical Reimbursement Experts (EU)(?)

Council Members in this Study Group: 15

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

David Sykes
Principal
PRMA Consulting Ltd

David Sykes is the Principal of PRMA Consulting, United Kingdom. He is an expert in pricing, reimbursement, and health outcomes within pharmaceutical and medical device sectors. Mr. Sykes has over 12 years of blue chip experience at J&J, Lilly, and Organon within global, European and UK roles. He has...

1 recent news post(s)

Related Study Groups

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Exubera - approvable is no longer reimbursable | 10-24-2007
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: David Sykes, Principal, PRMA Consulting Ltd

Exubera is the first major product to fail primarily due to Pfizer's inability to convince payors of it's value for money There is now significant additional risk in achieving market access after regulatory approval. Pricing and reimbursement decisions will play an increasingly important role in the...

Th | 06-18-2007
Analysis of: FDA Advisory Committee Did Not Recommend Approval of Rimonabant (ZIMULTI(R)) for Use in Obese and Overweight Patients With Associated Risks Factors | www.pipelinereview.com
Author: GLG Expert Contributor

This is a severe blow for the company which is now forced to consider external growth, but is not expert in out-of-France acquisitions. Rimonabant was meant to become THE sanofi-aventis blockbuster for the next 5 years at least. Also, the R&D productivity at sanofi-aventis will be questioned, since...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Consultancy, Pharma-Focused
  • Consultancy, Healthcare-Focused
  • Academic Medical Center/Hospital or Clinic
  • Professional or Industry Association*
  • Academic Institution*
  • Facility, Academic Medical Center
  • Individual/Small Consultancy
  • Other Health Insurer, Non-Profit
  • Other Healthcare Information Technology Company

Most Common Job Types:

  • Director
  • Principal
  • Chief Executive Officer
  • President
  • General Manager
  • Owner
  • Project Manager
  • Research Scientist

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-06T21:45:17.077